{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:36:09Z","timestamp":1794465369707,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04179-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:02:45Z","timestamp":1772186565000},"page":"1052-1060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-4368","authenticated-orcid":false,"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-2548","authenticated-orcid":false,"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditmarsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2018-4532","authenticated-orcid":false,"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-3807","authenticated-orcid":false,"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wuerdeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie L.","family":"Neild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6671-6878","authenticated-orcid":false,"given":"Andrew","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8755-8803","authenticated-orcid":false,"given":"Julie","family":"Butters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Ference","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Balinskaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"4179_CR1","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"Hu, P. et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 141, 1742\u20131759 (2020).","journal-title":"Circulation"},{"key":"4179_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490 (2013).","journal-title":"Eur. Heart J."},{"key":"4179_CR3","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","volume":"67","author":"L Perez de Isla","year":"2016","unstructured":"Perez de Isla, L. et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-Year SAFEHEART registry follow-up. J. Am. Coll. Cardiol. 67, 1278\u20131285 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4179_CR4","unstructured":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 398, 1713\u20131725 (2021)."},{"key":"4179_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132667","volume":"419","author":"J Lewek","year":"2025","unstructured":"Lewek, J. et al. Clinical reality and challenges with familial hypercholesterolemia patients\u2019 management. 2024 results from the Regional Center for Rare Diseases (RCRD) Registry in Poland. Int. J. Cardiol. 419, 132667 (2025).","journal-title":"Int. J. Cardiol."},{"key":"4179_CR6","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR7","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089\u20132099 (2012).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR8","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff, A. M. et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N. Engl. J. Med. 376, 1933\u20131942 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 318, 947\u2013956 (2017).","journal-title":"JAMA"},{"key":"4179_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"HPS3 TIMI55-REVEAL Collaborative Group","year":"2017","unstructured":"HPS3 TIMI55-REVEAL Collaborative Group et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217\u20131227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","volume":"43","author":"HPS3\/TIMI55-REVEAL Collaborative Group","year":"2022","unstructured":"HPS3\/TIMI55-REVEAL Collaborative Group et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur. Heart J. 43, 1416\u20131424 (2022).","journal-title":"Eur. Heart J."},{"key":"4179_CR12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.12380","volume":"78","author":"J Ford","year":"2014","unstructured":"Ford, J. et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 78, 498\u2013508 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"4179_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh, G. K. et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386, 452\u2013460 (2015).","journal-title":"Lancet"},{"key":"4179_CR14","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls, S. J. et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat. Med. 28, 1672\u20131678 (2022).","journal-title":"Nat. Med."},{"key":"4179_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne, C. M. et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J. Clin. Lipidol. 17, 491\u2013503 (2023).","journal-title":"J. Clin. Lipidol."},{"key":"4179_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls, S. J. et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N. Engl. J. Med. 393, 51\u201361 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray, K. K. et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol. 28, 1279\u20131289 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"4179_CR18","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray, K. K. et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg. Health Eur. 29, 100624 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"4179_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon, C. P. et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 6, 1\u20139 (2021).","journal-title":"JAMA Cardiol."},{"key":"4179_CR20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg, F. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 43, 3925\u20133946 (2022).","journal-title":"Eur. Heart J."},{"key":"4179_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"The Emerging Risk Factors Collaboration","year":"2009","unstructured":"The Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412\u2013423 (2009).","journal-title":"JAMA"},{"key":"4179_CR22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jama.1996.03540070040028","volume":"276","author":"AG Bostom","year":"1996","unstructured":"Bostom, A. G. et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 276, 544\u2013548 (1996).","journal-title":"JAMA"},{"key":"4179_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2022.07.009","volume":"356","author":"O Raitakari","year":"2022","unstructured":"Raitakari, O. et al. Long-term tracking and population characteristics of lipoprotein (a) in the Cardiovascular Risk in Young Finns Study. Atherosclerosis 356, 18\u201327 (2022).","journal-title":"Atherosclerosis"},{"key":"4179_CR24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso, R. et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am. Coll. Cardiol. 63, 1982\u20131989 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4179_CR25","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","volume":"322","author":"M Seed","year":"1990","unstructured":"Seed, M. et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 322, 1494\u20131499 (1990).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas, S. et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382, 244\u2013255 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue, M. L. et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N. Engl. J. Med. 387, 1855\u20131864 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4179_CR28","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen, S. E. et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 327, 1679\u20131687 (2022).","journal-title":"JAMA"},{"key":"4179_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen, S. E. et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): A randomized dose-ascending clinical trial. JAMA 330, 2075\u20132083 (2023).","journal-title":"JAMA"},{"key":"4179_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen, S. E. et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): A randomized clinical trial. JAMA 331, 1534\u20131543 (2024).","journal-title":"JAMA"},{"key":"4179_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls, S. J. et al. Oral muvalaplin for lowering of lipoprotein(a): A randomized clinical trial. JAMA 333, 222\u2013231 (2025).","journal-title":"JAMA"},{"key":"4179_CR32","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","volume":"37","author":"T Thomas","year":"2017","unstructured":"Thomas, T. et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 37, 1770\u20131775 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"4179_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","volume":"4","author":"A Langsted","year":"2016","unstructured":"Langsted, A., Kamstrup, P. R., Benn, M., Tybjaerg-Hansen, A. & Nordestgaard, B. G. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endo. 4, 577\u2013587 (2016).","journal-title":"Lancet Diabetes Endo."},{"key":"4179_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572\u2013580 (2012).","journal-title":"Lancet"},{"key":"4179_CR35","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38, 2478\u20132486 (2017).","journal-title":"Eur. Heart J."},{"key":"4179_CR36","first-page":"632","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas, K., Navar, A. M. & Kastelein, J. J. P. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. EHJ-CVP 8, 632 (2022).","journal-title":"EHJ-CVP"},{"key":"4179_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","volume":"21","author":"M Banach","year":"2022","unstructured":"Banach, M. et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc. Diabetol. 21, 263 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"4179_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","volume":"274","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls, S. J. et al. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am. Heart J. 274, 32\u201345 (2024).","journal-title":"Am. Heart J."},{"key":"4179_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamacardio.2018.1533","volume":"3","author":"SS Martin","year":"2018","unstructured":"Martin, S. S. et al. Comparison of low-density lipoprotein cholesterol assessment by Martin\/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: Insights from the FOURIER trial. JAMA Cardiol. 3, 749\u2013753 (2018).","journal-title":"JAMA Cardiol."},{"key":"4179_CR40","doi-asserted-by":"crossref","unstructured":"Rubin, D. B. Multiple Imputation for Nonresponse in Surveys (Wiley, 1987).","DOI":"10.1002\/9780470316696"}],"updated-by":[{"DOI":"10.1038\/s41591-026-04405-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04179-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:30:43Z","timestamp":1776490243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04179-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4179"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04179-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04405-7","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04405-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.N. received grant and\/or research support from AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience; and was a consultant for Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Silence Therapeutics, CSL Seqirus and Vaxxinity. A.J.N. has received research support from AstraZeneca, Amgen, Eli Lilly and Novartis; and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Seqirus, Eli Lilly, GSK, Novartis, Novo Nordisk, Sanofi Pasteur and Vaxxinity. C.M.B. has received grants or research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Roche Diagnostic, NIH, AHA and ADA; and is a consultant for 89Bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Eli Lilly, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk and Roche Diagnostic. K.K.R. reports research grants from Amgen, Amarin, Sanofi, Daiichi Sankyo and Ultragenyx to Imperial College London; consultancy to Novartis, Daiichi Sankyo, Kowa, Esperion, Novo Nordisk, MSD, Eli Lilly, Silence Therapeutics, AZ, New Amsterdam Pharma, Bayer, Beren Therapeutics, Cleerly, EmendoBio, Scribe, NodThera, CRISPR, Vaxxinity and Sanofi; fees for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Sanofi, Amgen, Esperion, Daiichi Sankyo, Dr Reddy\u2019s, Mankind and Macleods Pharma for symposia at international meetings; and holding stock options from NewAmsterdam Pharma, Scribe Therapeutics and Pemi31. A.M.N. has received research support to her institution from Amgen and Esperion; and personal fees for consulting from Amgen, Arrowhead, AstraZeneca, Bayer, Eli Lilly, Esperion, Janssen, Merck, NewAmsterdam, Novartis, Novo Nordisk, Pfizer, Roche and Silence Therapeutics. S.E.N. has received research funding to perform clinical trials from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Esperion Therapeutics, Medtronic, MyoKardia, NewAmsterdam Pharma, Novartis, Pfizer and Silence Therapeutics. A.C.G. has received research support to her institution from Amgen, Arrowhead, Esperion, Ionis, NewAmsterdam Pharma, Novartis, 89Bio Inc. and Sanofi; and personal fees for consulting from Ionis, NewAmsterdam Pharma, Regeneron and Eli Lilly. L.R.B. reports receiving research grants or consulting fees from Amgen, Sanofi, Novartis, HLS Therapeutics, Ionis and NewAmsterdam Pharma. B.A.F. has received research grants and consulting fees from Amgen, AstraZeneca, CiVi Biopharma, Daiichi Sankyo, DalCor, Eli Lilly, Esperion, Ionis Pharmaceuticals, Krka Pharmaceuticals, Merck, Mylan, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, The Medicines Company and Viatris. U.L. has received fees for consulting or lectures from Amgen, Boehringer, Daiichi Sankyo, NewAmsterdam Pharma, Novartis, Sanofi; Leipzig University received research funding from Amgen, Daiichi Sankyo, Novartis and Sanofi. M.B. has received grant(s) and\/or research support from Amgen, Daiichi Sankyo, Mylan\/Viatris and Sanofi; and has served as a consultant and\/or received speaker fees from Adamed, Amgen, Exceed Pharma, Daiichi Sankyo, Esperion, Kogen, KRKA, Lilly, MSD, Mylan\/Viatris, NewAmsterdam Pharma, Novartis, Novo Nordisk, Polpharma, Sanofi, Teva and Zentiva. R.M. reports institutional research payments from Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, MediaSphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global BioAccess Fund Management and Sanofi US Services, Inc.; has received personal fees from Elixir Medical, IQVIA, Medtronic, Medscape\/WebMD Global and Novo Nordisk; and has equity in Elixir Medical, Stel and ControlRad (spouse). A.L.C. has received honoraria, lecture fees or research grants from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, Novo Nordisk, Regeneron, Sanofi, Ultragenyx and Viatris. M.S. serves as a consultant for and\/or has received research support from Lexicon, Amarin, NewAmsterdam Pharma, Silence, Sanofi, Regeneron and Tourmaline; and receives salary support from CPC, a nonprofit academic research organization affiliated with the University of Colorado, which receives or has received research grant\/consulting funding between July 2021 and July 2024 from Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma Godo Kaisha, Amgen Inc., Anthos Therapeutics, Inc., ARCA biopharma, Inc., Arrowhead Pharmaceuticals, AstraZeneca Pharma India, AstraZeneca UK Ltd, Bayer, Bayer Aktiengesellschaft, Bayer Pharma AG, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute LLC, Bristol Myers Squibb, Cleerly, Inc., Colorado Dept. of Public Health and Environment, Congress Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EPG Communication Holdings Ltd., Esperion Therapeutics, Inc., Faraday Pharmaceuticals, Inc., HeartFlow Inc., Insmed, Ionis Pharmaceuticals, IQVIA Inc., Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Janssen Scientific Affairs LLC, Lexicon Pharmaceuticals, Inc., Medpace, Inc., Medscape, Merck Sharp & Dohme Corp., Nectero Medical, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer, PPD Development, L.P., Prothena Biosciences Limited, Regeneron, Regents of the University of Colorado (aka UCD), Sanifit Therapeutics S.A., Sanofi, Silence Therapeutics PLC, Stanford University, Stealth BioTherapeutics Inc., The Brigham and Women\u2019s Hospital, Thrombosis Research Institute, Tourmaline Bio, Inc., University of Colorado, University of Colorado Denver, University of Pittsburgh, VarmX, Verve Therapeutics and WraSer, LLC. V.B. is an employee of Medpace. M.D., J.J.P.K., E.W., A.L.N., D.K., A.H. and M.H.D. are employees of NewAmsterdam Pharma and hold stocks or options. J.B. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}